↓ Skip to main content

Anthracycline Chemotherapy and Cardiotoxicity

Overview of attention for article published in Cardiovascular Drugs and Therapy, February 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

2 tweeters
1 Wikipedia page


122 Dimensions

Readers on

301 Mendeley
Anthracycline Chemotherapy and Cardiotoxicity
Published in
Cardiovascular Drugs and Therapy, February 2017
DOI 10.1007/s10557-016-6711-0
Pubmed ID

John V McGowan, Robin Chung, Angshuman Maulik, Izabela Piotrowska, J Malcolm Walker, Derek M Yellon


Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane. New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon. Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today's anthracycline-treated cancer patients may become tomorrow's cardiac patient.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 301 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 301 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 50 17%
Student > Bachelor 48 16%
Student > Master 42 14%
Unspecified 40 13%
Researcher 34 11%
Other 87 29%
Readers by discipline Count As %
Medicine and Dentistry 89 30%
Biochemistry, Genetics and Molecular Biology 59 20%
Unspecified 55 18%
Pharmacology, Toxicology and Pharmaceutical Science 27 9%
Chemistry 18 6%
Other 53 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2019.
All research outputs
of 13,205,256 outputs
Outputs from Cardiovascular Drugs and Therapy
of 392 outputs
Outputs of similar age
of 256,939 outputs
Outputs of similar age from Cardiovascular Drugs and Therapy
of 10 outputs
Altmetric has tracked 13,205,256 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 392 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 256,939 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.